CXCR4 expression in lung carcinogenesis: Evaluating gender-specific differences in survival outcomes based on CXCR4 expression in early stage non-small cell lung cancer patients

Andrea S. Fung, Karen Kopciuk, Michelle L. Dean, Adrijana D'Silva, Shannon Otsuka, Alexander Klimowicz, Desiree Hao, Don Morris, D. Gwyn Bebb

1 Tom Baker Cancer Centre, Calgary, Alberta, Canada, 2 Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada, 3 Department of Oncology, Queen’s University, Kingston, Ontario, Canada

Abstract

Introduction

Evidence suggests that the expression of certain cytokine receptors increases with lung cancer evolution. Overexpression of the cytokine receptor CXCR4 is associated with poor outcomes in stage IV non-small cell lung cancer (NSCLC), with shorter survival in females with high CXCR4 expression. This study quantifies CXCR4 expression in early stage disease and evaluates its association with gender-specific recurrence-free (RFS) and overall survival (OS) in resected stage I-III NSCLC patients.

Methods

Patient characteristics and clinical outcomes were obtained from the Glans-Look Lung Cancer (G-LLC) database for early stage NSCLC patients diagnosed between 2003–2006 at the Tom Baker Cancer Centre (TBCC). CXCR4 expression was quantified on tissue microarrays (TMA). Median RFS and OS were evaluated by gender using Kaplan-Meier analyses. CXCR4 expression and outcome data were analyzed using Cox proportional hazards (PH) and multi-state models (MSM).

Results

176 stage I-III NSCLC patients were identified. CXCR4 expression was lower in early stage NSCLC patients, with a mean CXCR4 expression of 1729 (SD 1083) compared to 2640 (SD 1541) in stage IV patients. On Kaplan-Meier, median RFS by gender was similar (male 52.8 months vs. female 54.5 months) as was median OS (male 80.9 months vs. female 89.0 months), and there was no significant difference in RFS (p = 0.60) or OS (p = 0.30) by gender and CXCR4 groups over follow-up. By multivariable analysis, CXCR4 expression was
not prognostic for RFS (Hazard Ratio (HR) = 1.00, p = 0.73) or OS (HR = 1.00, p = 0.44), and no gender difference was observed.

Conclusions
CXCR4 expression increases with stage progression in NSCLC but is not prognostic in early stage NSCLC patients of either gender. Mechanisms by which CXCR4 expression increases during lung carcinogenesis warrant further exploration and testing in clinical trials.

Introduction
Cytokines and their receptors have been implicated in tumor progression [1–3], and evidence suggests that the expression of some cytokine receptors increases with cancer evolution [4]. The cytokine receptor CXCR4 and its ligand stromal cell derived factor-1 (SDF-1) can activate signaling through the phosphoinositol-3-kinase (PI3K) and mitogen activated protein kinase (MAPK) pathways, and have been implicated in cell migration, invasion and angiogenesis [5–8]. Furthermore, the CXCR4/SDF-1 axis may be involved in regulating development of organ-specific metastases [5].

Overexpression of CXCR4 has been associated with poor outcomes in patients with advanced cancer, including breast, head and neck, ovarian, and non-small cell lung cancer (NSCLC), among others [4, 9–14]. Increased CXCR4 expression has been associated with nodal and distant metastases, and worse survival in NSCLC patients [7, 8, 15, 16]. Studies suggest that nuclear or cytomembranous CXCR4 expression is differentially associated with survival, with better survival outcomes associated with nuclear staining, and an association between distant metastases and worse survival with cytomembranous staining [8, 16, 17].

Previously, we demonstrated a gender-specific difference in outcomes of stage IV NSCLC patients according to CXCR4 expression, with shorter survival in females with high CXCR4 expression [14]. However, the extent of CXCR4 expression in early versus advanced NSCLC and its relationship to outcome and gender is not known. Here, we aimed to characterize gender-specific differences in survival based on CXCR4 expression in resected stage I-III NSCLC patients.

Materials and methods
Patient characteristics
A retrospective analysis of stage I-III NSCLC patients (AJCC 7th edition) diagnosed at the Tom Baker Cancer Centre (Calgary, Canada) between 2003–2006 was undertaken. Patient characteristics, diagnostic, treatment and outcome data were collected through chart review and kept in the Glans-Look Lung Cancer (G-LLC) database. Stage IV patient data were also collected from the G-LLC database. All patient data and tissue samples were de-identified, and patient records and tissue samples were accessed for analyses from August 2009 to July 2010. Research ethics board (REB) approval was obtained from the Health Research Ethics Board of Alberta Cancer Committee (HREBA-CC) prior to study initiation, and research was completed in accordance with the Tri-Council Policy Statement on Research with Human Subjects.
Quantification of CXCR4 expression

Tissue microarrays (TMA) were generated from formalin-fixed paraffin-embedded samples from archived biopsy or surgical specimens. Representative cores (0.6mm) were taken in triplicate from each specimen. Fluorescent immunohistochemical staining (IHC), quantification and analysis of CXCR4 expression were completed as previously described by Otsuka et al. [14]. Briefly, 5 μm sections were cut from TMA blocks and stained using a 1:500 dilution of anti-pan-cytokeratin mouse monoclonal antibody (Dako) and a 1:25 dilution of an anti-CXCR4 rabbit monoclonal antibody (clone UMB2, Biotrend, Köln, Germany) to identify tumor cells and CXCR4 expression, respectively [14]. Images were acquired using filters for DAPI (nuclear compartment), Cy3 (cytokeratin-positive tumor cells and the cytosolic compartment), and Cy5 (CXCR4 biomarker). Nuclear and cytomembranous CXCR4 expression was characterized and CXCR4 levels were expressed as a tumor-specific automated quantitative analysis (AQUA) score, which represented the maximum signal intensity per tumor area [14]. A definite AQUA score cut-point to differentiate between low vs. high CXCR4 expression was not identified; therefore, mean CXCR4$_{\text{max}}$ expression, in addition to ranges of AQUA scores were utilized to compare the level of CXCR4 expression between groups.

Statistical analysis

Survival outcomes included recurrence, recurrence-free survival (RFS), defined as the time from the end of treatment to recurrence or death; and overall survival (OS), defined as time from diagnosis to death from any cause. CXCR4 expression and survival outcomes were analyzed using Kaplan-Meier curves, Cox proportional hazards (PH) and multi-state models (MSM) [18], which accounted for the effect of treatments received following recurrence. CXCR4 expression levels were compared between groups using a two sample $t$-test. Statistical analyses were completed using R version 3.5.1 software.

Results

Patient characteristics

One hundred and seventy six stage I-III patients with TMA-derived CXCR4 data were identified. Baseline patient characteristics are summarized in Table 1. The mean age at diagnosis was 65. There were 52.8% females, with 25.6% current smokers, 60.8% ex-smokers and 11.9% never smokers. There were 114 patients (64.8%) with adenocarcinoma, 59.7% had stage I disease, and 77.3% were lymph node negative (N0). Over a maximum follow up of 17.4 years, there were 128 deaths (72.7%) and 88 patients (50%) had a recurrence (Table 1).

An updated analysis of 147 stage IV patients (75 females, 72 males) identified in the G-LLC database was also performed with a detailed summary of their characteristics also shown in Table 1.

Of all stage I-III patients, 62 patients (35.2%) received neoadjuvant/adjuvant chemotherapy, while 18 (10.2%) received adjuvant radiation. Of the 88 patients who recurred, 29 (33.0%) received systemic treatment (chemotherapy, targeted therapy or immunotherapy) post-recurrence, and 54 (61.4%) received radiation (Table 2). The treatments received after recurrence was similar across genders.

CXCR4 expression

A range of CXCR4 expression was observed in early stage NSCLC patients; representative IHC images showing low versus high CXCR4 expression are shown in Fig 1. Mean CXCR4$_{\text{max}}$ expression was 1729 (SD 1083) in stage I-III patients, which was lower than the mean of 2640
|                   | Stage I-III | Female (n = 93) | %    | Male (n = 83) | %    | Stage IV | %    |
|------------------|------------|----------------|------|--------------|------|----------|------|
| **Gender**       |            |                |      |              |      |          |      |
| Female           | 93         | 52.8           | 93   | 100          | -    |          | 75   | 51.0 |
| Male             | 83         | 47.2           | -    | -            | 83   | 100      | 72   | 49.0 |
| **Smoking Status** |         |                |      |              |      |          |      |
| Current          | 45         | 25.6           | 25   | 26.9         | 20   |          | 44   | 30.0 |
| Ex-smoker        | 107        | 60.8           | 48   | 51.6         | 59   |          | 78   | 53.1 |
| Never            | 21         | 11.9           | 19   | 20.4         | 2    |          | 20   | 13.6 |
| Unknown          | 3          | 1.7            | 1    | 1.1          | 2    |          | 5    | 3.4  |
| **Stage**        |            |                |      |              |      |          |      |
| IA               | 39         | 22.2           | 25   | 26.9         | 14   |          | 16.9 |
| IB               | 66         | 37.5           | 36   | 38.7         | 30   |          | 36.2 |
| IIA              | 26         | 14.8           | 9    | 9.7          | 17   |          | 20.5 |
| IIB              | 28         | 15.9           | 14   | 15.1         | 14   |          | 16.9 |
| IIIA             | 17         | 9.7            | 9    | 9.7          | 8    |          | 9.6  |
| IV               |            |                |      |              |      |          | 147  | 100  |
| **Histology**    |            |                |      |              |      |          |      |
| Adenocarcinoma   | 114        | 64.8           | 70   | 75.3         | 44   |          | 53   | 50.3 |
| Squamous cell carcinoma | 51   | 29            | 14   | 15.1         | 37   |          | 44.6 | 25.9 |
| Adenosquamous carcinoma | 3    | 1.7          | 2    | 2.2          | 1    |          | 1.2  | 0.7  |
| Large cell carcinoma | 7    | 4             | 6    | 6.5          | 1    |          | 1.2  | 6.8  |
| Other NSCLC      | 1          | 0.6           | 1    | 1.1          | 0    |          | 0    | 16.3 |
| **Nodal status** |            |                |      |              |      |          |      |
| N0               | 136        | 77.3           | 73   | 78.5         | 63   |          | 75.9 | 21   |
| N1               | 31         | 17.6           | 16   | 17.2         | 15   |          | 18.1 | 6    |
| N2               | 9          | 5.1            | 4    | 4.3          | 5    |          | 6    | 52.4 |
| N3               |            |                |      |              |      |          | 24   | 16.3 |
| X                |            |                |      |              |      |          | 19   | 12.9 |
| **Chemotherapy** |            |                |      |              |      |          |      |
| Yes              | 75         | 42.6           | 37   | 39.8         | 38   |          | 45.8 |
| - Neoadjuvant/Adjuvant | 62 | 35.2       | 31   | 33.3         | 31   |          | 37.4 |
| - Palliative     | 13         | 7.4            | 6    | 6.5          | 7    |          | 8.4  | 24.5 |
| No               | 101        | 57.4           | 56   | 60.2         | 45   |          | 54.2 | 111  |
| **Radiation therapy** |         |                |      |              |      |          |      |
| Yes              | 60         | 34.1           | 31   | 33.3         | 29   |          | 34.9 |
| - Neoadjuvant/Adjuvant | 18 | 10.2       | 10   | 10.8         | 8    |          | 9.6  |
| - Palliative     | 42         | 23.9           | 21   | 22.6         | 21   |          | 25.3 | 118  |
| No               | 116        | 65.9           | 62   | 66.7         | 54   |          | 65.1 | 29   |
| **CXCR4 (max)** |            |                |      |              |      |          |      |
| Mean (25%, 75%)  | 1729       | (1096, 1937)   | 1567 | (1050, 1712) | 1911 | (1174, 2237) | 2640 | (1,681, 3,151) |
| **Age at Diagnosis** |         |                |      |              |      |          |      |
| Mean (25%, 75%)  | 65         | (58.3, 73.4)   | 64.7 | (58.0, 73.4) | 65.5 | (59.3, 73.2) | 67.6 | (59.5, 76.0) |
| **Recurrence**   |            |                |      |              |      |          |      |
| Yes              | 88         | 50             | 49   | 52.7         | 39   |          | 47   |
| No               | 88         | 50             | 44   | 47.3         | 44   |          | 53   |
| **Deaths**       |            |                |      |              |      |          |      |
| Yes              | 128        | 72.7           | 65   | 69.9         | 63   |          | 75.9 | 147  |
| No               | 48         | 27.3           | 28   | 30.1         | 20   |          | 24.1 | 0    |

https://doi.org/10.1371/journal.pone.0241240.t001
(SD 1541) observed in stage IV patients. There appeared to be an increase in mean \( \text{CXCR4}_{\text{Max}} \) expression with stage progression, with a statistically significant difference in mean \( \text{CXCR4}_{\text{Max}} \) expression between stage I vs. IV (1689 ±1257 vs. 2640 ±1541, \( p < 0.001 \)), stage II vs. IV (1752 ±719 vs. 2640 ±1541, \( p < 0.001 \)) and stage III vs. IV (1900 ±890 vs. 2640 ±1541, \( p = 0.006 \)) patients (Fig 2 top panel); however, the differences in CXCR4 expression between stage I vs. II, I vs. III, and II vs. III patients were not statistically significant (\( p \)-values >0.05). Maximum CXCR4 expression levels >2500 were more frequent in stage IV versus stage I-III patients (Fig 2 bottom panel).

The nuclear and cytomembranous components of CXCR4 staining were both higher in stage IV patients compared to early stage patients (\( p < 0.05 \)), and this was consistent across

Table 2. Treatments received after recurrence for all patients and by gender.

| At Recurrence | All (n = 88) | % | Female (n = 49) | % | Male (n = 39) | % |
|---------------|-------------|---|----------------|---|---------------|---|
| Any treatment post recurrence | | | | | | |
| Yes | 62 | 70.5 | 34 | 69.4 | 28 | 71.8 |
| No | 26 | 29.5 | 15 | 30.6 | 11 | 28.2 |
| Systemic treatment post recurrence | | | | | | |
| Yes | 29 | 33.0 | 16 | 32.7 | 13 | 33.3 |
| No | 59 | 67.1 | 33 | 67.4 | 26 | 66.7 |
| Radiation post recurrence | | | | | | |
| Yes | 54 | 61.4 | 30 | 61.2 | 24 | 61.5 |
| No | 34 | 38.6 | 19 | 38.8 | 15 | 38.5 |

https://doi.org/10.1371/journal.pone.0241240.t002

Fig 1. CXCR4 immunohistochemical (IHC) staining. CXCR4 expression in negative and positive (HeLa) control cells (left panel). CXCR4 staining in early stage non-small cell lung cancer patients, with low (right top panel) and high CXCR4 expression (right bottom panel) shown in red. DAPI nuclear staining shown in blue, and PCK tumor cytosolic component shown in green.

https://doi.org/10.1371/journal.pone.0241240.g001
Fig 2. CXCR4 expression is lower in early stage compared to late stage NSCLC patients. Mean CXCR4_max expression increased with stage progression, with higher CXCR4 expression in stage IV NSCLC patients (top panel); error bars represent standard error of the mean. Maximum CXCR4 expression levels >2500 were less frequent in early stage lung cancer patients compared to late stage patients (bottom panel).

https://doi.org/10.1371/journal.pone.0241240.g002
genders. Interestingly, males with early stage NSCLC had higher nuclear expression of CXCR4 than females (mean of 1911 ±1107 vs. 1567 ±1040, p = 0.049). Likewise, nuclear CXCR4_max expression levels >2500 were more frequent in males compared to females (18.1% vs. 10.7%) in early stage NSCLC patients.

Two patients had both resected and recurrent metastatic tissue available—the female had higher CXCR4 expression (both nuclear and cytomembranous) in the stage IV than in the early stage sample, whereas the male patient’s CXCR4 expression was similar, irrespective of stage (Fig 3). Both patients recurred, with the male recurring locally and the female developing distant metastatic recurrence.

Recurrence and survival outcomes

In this early stage patient cohort, CXCR4 expression did not independently predict for recurrence, RFS or OS (Table 3). Similarly, there was no differential predictive effect by gender or following recurrence for death in the multi-state model (Table 3). On Kaplan-Meier analysis, no gender difference in RFS (p = 0.60) or OS (p = 0.30) by gender and CXCR4 expression groups based on median splits were observed and median survival times were similar (RFS: male 52.8 months vs. female 54.5 months, OS: male 80.9 months vs. female 89.0 months; Fig 4 top and bottom panels, respectively). However, patients of either gender with CXCR4_max expression greater than the median split appeared to have a trend towards worse RFS and OS starting approximately 3 years from diagnosis. When stage IV patients were included with the early stage patients in a multivariable adjusted Cox PH model, CXCR4 expression did not independently, or synergistically with gender or stage, predict for OS (HR = 1.0001, p = 0.32).
In this study, we report that CXCR4 expression in early stage resected NSCLC patients was substantially lower than previously reported for stage IV patients by Otsuka et al. [14]. Our data showed an increase in CXCR4 expression with stage progression. We observed an increase in both the nuclear and cytomembranous components of CXCR4 expression in late stage patients when compared to early stage patients. In contrast to metastatic NSCLC, we found that CXCR4 expression was not prognostic of survival outcomes in stage I-III patients. However, there was a trend towards worse RFS and OS in patients with a CXCR4 expression greater than the median split in either gender. Overall, our data suggest that CXCR4 expression increases with cancer progression, acquiring clinical significance only in the metastatic setting. A role for chemokine receptor axes in tumor progression, invasion and metastasis has been suggested before [1–4, 6]. Our analysis supports an association between tumor progression and CXCR4 expression in NSCLC, but does not address causality.

Our cohort included a small number of patients with stage IIIA disease, no stage IIIB patients, and only 9 patients with N2 disease. Consequently, analysis of the impact of CXCR4 expression on survival outcomes in stage III patients was limited. On multivariable survival analysis, we found no association between CXCR4 expression and lymph node status in early stage patients; however, our study was limited by a small number of node-positive patients and a robust analysis could not be completed. A plausible explanation is that the resected stage III cases represent those with minimal presurgical evidence of nodal disease based on imaging and mediastinal staging. In such cases, the extent of metastatic capability is likely not as well developed as in cases where disease has metastasized to distal organs.

A meta-analysis by Liang et al. found an association between CXCR4 overexpression and lymph node metastasis, distant metastasis, and OS [15]; however, the patient population was quite heterogeneous (i.e. included stage I-IV patients as well as small cell lung cancer patients), making comparison to our patient population difficult. It is possible that the impact of the CXCR4/SDF-1 axis is more prominent in patients with lymph node metastasis, or after recurrence, as this pathway is implicated in cell migration, invasion, and possible homing to different organ sites of metastases [4, 7, 8, 19]. Interestingly, the majority of stage IV patients (n = 107, 72.8%) in our study had node-positive disease, suggesting a possible relationship between higher CXCR4 levels in stage IV patients and development of lymph node and distant metastases. Further studies should be considered to evaluate the association between CXCR4 expression (nuclear vs. cytomembranous) and development of organ-specific sites of metastases.

### Table 3. Impact of CXCR4 expression on recurrence, RFS and OS.

| Phenomenon          | HR (95% CI) | Pr(>|z|) |
|---------------------|-------------|---------|
| Recurrence          |             |         |
| CXCR4 (max)         | 1.0000      | 0.9998, 1.0000 | 0.87 |
| RFS                 | 1.0000      | 0.9998, 1.0000 | 0.73 |
| OS                  | 1.0001      | 0.9999, 1.0000 | 0.44 |
| Multi-state (recurrence—death transition) | 1.0002 | 0.9999, 1.0004 | 0.08 |

*All Cox PH models adjusted for stage, nodal status, histology, gender, age at diagnosis, smoking status, systemic and radiation therapy before recurrence; the extended stay Markov PH multistate model included post recurrence treatment.*

https://doi.org/10.1371/journal.pone.0241240.t003
Fig 4. No gender-specific difference in survival outcomes by CXCR4 expression. There was no difference in recurrence-free survival (top panel) or overall survival (bottom panel) based on gender in patients with high or low levels of CXCR4 expression based on median splits.

https://doi.org/10.1371/journal.pone.0241240.g004
Otsuka et al. previously reported a gender-specific difference in survival, with worse outcomes in females with high CXCR4 expression [14]. We did not observe a difference in survival outcomes based on gender; however, we did note higher nuclear CXCR4 expression in males compared to females in the early stage setting. Previous studies have shown that nuclear expression of CXCR4 is associated with better survival than cytomembranous expression, and this might be due to less tumor-promoting effects of the receptor with nuclear localization compared to when the receptor is in the cytomembranous compartment [8, 16]. It is possible that the greater nuclear expression noted in males with early stage NSCLC could account for the different survival outcomes between genders. In addition, differences in nuclear vs. cytomembranous expression could lead to different risks for development of recurrent or metastatic disease.

There are limitations in the current study. Firstly, we are limited by the retrospective nature of the analysis; however, our data collection was comprehensive and included a substantial number of early stage patients in comparison to other published studies evaluating CXCR4 expression in lung cancer patients. Secondly, the small number of stage III patients (with no stage IIIB patients), as well as few node-positive patients in our population, did not allow for a robust analysis of more advanced stage III disease. However, despite this, we were still able to show an increase in CXCR4 expression with stage progression. Finally, there was limited data on sites of metastases in patients who recurred; therefore, we were unable to evaluate for an association between CXCR4 expression and development of organ-specific sites of metastases.

Targeted therapies have been developed to inhibit the CXCR4/SDF-1 axis, and have been evaluated in various cancers [2, 20–22]. Despite disappointing results in trials utilizing anti-CXCR4 strategies [23, 24], the CXCR4/SDF-1 axis warrants further study to define its role in tumor progression, recurrence, and metastasis, as well as elucidate the impact on the tumor microenvironment. Furthermore, the function of the CXCR4/SDF-1 axis in immune biology suggests a potential therapeutic role for anti-CXCR4 strategies with immunotherapy [25]. Trials are ongoing to evaluate this combination (NCT03193190, NCT03281369, NCT03337698).

Conclusion

CXCR4 expression is significantly lower in stage I-III than in stage IV NSCLC patients. Its expression does not predict survival outcomes in early stage patients, and no gender difference was identified between CXCR4 expression and survival. Mechanisms by which CXCR4 expression increases during lung carcinogenesis warrant further exploration and testing in clinical trials.

Author Contributions

Conceptualization: D. Gwyn Bebb.
Data curation: Michelle L. Dean, Adrijana D’Silva, Shannon Otsuka, Alexander Klimowicz, Desiree Hao, Don Morris, D. Gwyn Bebb.
Formal analysis: Andrea S. Fung, Karen Kopciuk, Michelle L. Dean.
Methodology: Karen Kopciuk, Michelle L. Dean, Adrijana D’Silva, Shannon Otsuka, Alexander Klimowicz, D. Gwyn Bebb.
Supervision: D. Gwyn Bebb.
Writing – original draft: Andrea S. Fung.
Writing – review & editing: Andrea S. Fung, Karen Kopciuk, Michelle L. Dean, Adrijana D’Silva, Shannon Otsuka, Alexander Klimowicz, Desiree Hao, Don Morris, D. Gwyn Bebb.
References

1. Balkwill F. Cancer and the chemokine network. Nature Reviews Cancer 2004; 4(7):540–550 https://doi.org/10.1038/nrc1388 PMID: 15229479

2. Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EGE, et al. A review on CXCR4/CXCL12 axis in oncology: No place to hide. Euro J Cancer 2013; 49:219–230. https://doi.org/10.1016/j.ejca.2012.05.005 PMID: 22683307

3. Wightman SC, Uppal A, Pitroda SP, Ganai S, Burnette B, Stack M, et al. Oncogenic CXCL10 signalling drives metastasis development and poor clinical outcome. British Journal of Cancer 2015; 113(2):327–335 https://doi.org/10.1038/bjc.2015.193 PMID: 26042934

4. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumor suppressor pVHL. Nature 2003; 425:307–311 https://doi.org/10.1038/nature01874 PMID: 13679920

5. Belperio JA, Phillips RJ, Burdick MD, Lutz M, Keane M, Strieter R. The SDF-1/CXCL12/CXCR4 biological axis in non-small cell lung cancer metastases. Chest 2004. 125(5 Suppl): 156S. https://doi.org/10.1378/chest.125.5_suppl.156s PMID: 15136483

6. Otsuka S, Bebb G. The CXCR4/SDF-1 chemokine receptor axis: A new target therapeutic for non-small cell lung cancer. Journal of Thoracic Oncology 2008; 3(12):1379 –1383 https://doi.org/10.1097/JTO.0b013e31818dada99 PMID: 19057260

7. Hu J, Deng X, Bian X, Li G, Tong Y, Li Y, et al. The expression of functional chemokine receptor CXCR4 is associated with the metastatic potential of human nasopharyngeal carcinoma. Clin Cancer Res 2005; 11:4658–4665. https://doi.org/10.1158/1078-0432.CCR-04-1798 PMID: 16000558

8. Jiang YP, Wu XH, Shi B, Wu WX, Yin GR. Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression. Gynecol Oncol 2006; 103:226–233 https://doi.org/10.1016/j.ygyno.2006.02.036 PMID: 16631235

9. Kang H, Watkins G, Parr C, Douglas-Jones A, Mansel RE, Jiang WG. Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Res 2005; 7:R402–R410 https://doi.org/10.1186/bcr1022 PMID: 15987445

10. Gangadhar T, Nandi S, Salgia R. The role of chemokine receptor CXCR4 in lung cancer. Cancer Biology and Therapy 2010; 9(6):409–416 https://doi.org/10.4161/cbt.9.6.11233 PMID: 21590177

11. Putter H, Fico M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Statist. Med. 2007; 26:2389–2430. https://doi.org/10.1002/sim.2712 PMID: 17031868

12. Wagner PL, Hyjek E, Vazquez MF, Meherally D, Liu YF, Chadwick PA, et al. CXCL12 and CXCR4 in adenocarcinoma of the lung: Association with metastasis and survival. J Thorac Cardiovasc Surg 2009; 137:615–21 https://doi.org/10.1016/j.jtcvs.2008.07.039 PMID: 19258077

13. Peng SB, Zhang X, Paul D, Kays LM, Gough W, Stewart J, et al. Identification of LY2510924, a Novel Cyclic Peptide CXCR4 Antagonist that Exhibits Antitumor Activities in Solid Tumor and Breast Cancer
21. Rubie C, Frick VO, Ghadjar P, Wagner M, Justinger C, Faust SK, et al. CXC receptor-4 mRNA silencing abrogates CXCL12-induced migration of colorectal cancer cells. J Transl Med. 2011; 9:22. https://doi.org/10.1186/1479-5876-9-22 PMID: 21349176

22. Singla AK, Downey CM, Bebb DG, Jirik FR. Characterization of a murine model of metastatic human non-small cell lung cancer and effect of CXCR4 inhibition on the growth of metastases. Oncoscience 2015; 2(3):263–271. https://doi.org/10.18632/oncoscience.117 PMID: 25897429

23. Salgia R, Stille JR, Weaver RW, McCleod M, Hamid O, Polzer J, et al. A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer. Lung Cancer 2017; 105:7–13 https://doi.org/10.1016/j.lungcan.2016.12.020 PMID: 28236984

24. Hainsworth JD, Reeves JA, Mace JR, Crane EJ, Hamid O, Stille JR, et al. A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC). Target Oncol. 2016 Oct; 11(5):643–653. https://doi.org/10.1007/s11523-016-0434-9 PMID: 27154357

25. Eckert F, Schilbach K, Klumpp L, Bardoscia L, Sezgin EC, Schwab M, et al. Potential Role of CXCR4 Targeting in the Context of Radiotherapy and Immunotherapy of Cancer. Front Immunol. 2018; 9:3018. https://doi.org/10.3389/fimmu.2018.03018 PMID: 30622535